Latest Actinic keratosis Stories
A representative for Likewise Skincare offers her response to an article published on sfgate.com written by Dr. Tony Brayer which discusses the long-term effects of sun damage. Bohemia, NY (PRWEB) August 20, 2012 August 20th, Likewise Skincare, producer of anti aging cream, reacts to an article published on sfgate.com concerning the various effects from sun damage that can plague people as they get older if they do not consider proper UV protection. In the article, Dr. Tony Brayer, chief...
Skin cancer is the most common form of cancer in the United States. Water’s Edge Dermatology, a leading practice with 16 locations in Southeast Florida, shares new studies, pharmaceuticals and skin cancer treatments and tips for Americans to protect their skin and prevent skin cancer. Palm Beach Gardens, FL (PRWEB) May 01, 2012 Skin cancer is the most common form of cancer in the United States. And during Skin Cancer Awareness Month this May, Americans can learn of the many ways to...
A new topical gel now available by prescription significantly decreases the amount of time needed to treat actinic keratosis, a skin condition that is a common precursor to skin cancer, according to a multi-center trial led by researchers at Mount Sinai School of Medicine. The gel, called ingenol mebutate, is applied to the skin for just a few days, making it quicker and even more effective as current therapies require weeks to months to apply. The Phase III study results of the trial are...
PARSIPPANY, New Jersey, March 14, 2012 /PRNewswire/ -- Ingenol mebutate was proven efficacious with a once-daily application for only 2 or 3 days Today, the New England Journal of Medicine (NEJM) published an analysis of pooled results from LEO Pharma's four Phase III clinical trials for ingenol mebutate gel, demonstrating that ingenol mebutate gel is safe and effective for the treatment of actinic keratoses (AKs) on the...
PARSIPPANY, N.J., Feb. 15, 2012 /PRNewswire/ -- The American Academy of Dermatology (AAD) and LEO Pharma want Americans to know that sunburns and premature aging aren't the only indications that their skin has been damaged by cumulative exposure to the sun. Research-based pharmaceutical company LEO Pharma has partnered with the AAD to launch Listen To Your Skin, a campaign aimed to raise awareness about the consequences and symptoms of cumulative sun damage including actinic...
COPENHAGEN, Denmark, January 26, 2012 /PRNewswire/ -- LEO Pharma today announced that Picato(R) (ingenol mebutate) gel (0.015%, 0.05%) has been approved by the US Food and Drug Administration (FDA) as a treatment for actinic keratoses (AK) on the face, scalp, trunk and extremities. Picato(R) gel is a once-daily, field-directed topical treatment for AK, a potential precursor to non-melanoma skin cancer caused by cumulative sun exposure. Treatment with Picato(R) gel is completed...
PARSIPPANY, N.J., Jan. 25, 2012 /PRNewswire/ -- LEO Pharma announced today that the U.S. Food and Drug Administration (FDA) approved Picato® (ingenol mebutate) gel (0.015%, 0.05%) for the topical treatment of actinic keratosis (AK). AK is a precancerous condition caused by cumulative sun exposure that has the potential to progress to squamous cell carcinoma (SCC), the second most common type of skin cancer.[1],[2] Picato® 0.015% gel is used once daily on the face and scalp for...
FLORHAM PARK, N.J., May 19, 2011 /PRNewswire/ -- PharmaDerm, a division of Nycomed US Inc., announced today that is has launched AK Connect, a patient resource program that contains information tailored to different types of patients about diagnosis, symptoms, treatment and support for actinic keratosis (AK). Now physicians who treat patients with AK have a new resource to help better inform patients about this potentially serious skin condition that affects millions of Americans.(1,2)...
New research from North Carolina State University shows that a "gatekeeper" protein plays an important role in skin-cancer prevention in humans and lab mice.The protein, C/EBP alpha, is normally abundantly expressed to help protect skin cells from DNA damage when humans are exposed to sunlight. The NC State research shows, however, that the protein is not expressed when certain human skin cancers are present.Moreover, when the protein is inactivated in special lab mice exposed to small...
HAYWARD, Calif., May 18, 2011 /PRNewswire/ -- Solta Medical, Inc. (Nasdaq: SLTM), the pioneer in fractional resurfacing and non-invasive skin tightening and a global market leader in aesthetic skin treatments, recently launched the "Take a Swing at the Sun" Facebook contest. This industry-first contest encourages consumers to share how they protect themselves from the sun and in doing so are entered to win a trip for four to Las Vegas. The contest winners will attend the Justin...
